Shantou University Medical College, Brain Function and Disease Laboratory, Shantou, #22 Road Xinling, Guangdong 515041, China.
Department of Neurology, Yunfu People's Hospital, Yunfu, Guangdong 527300, China.
Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.
Cannabinoids are compounds isolated from cannabis and are also widely present in both nervous and immune systems of animals. In recent years, with in-depth research on cannabinoids, their clinical medicinal value has been evaluated, and many exciting achievements have been continuously accumulating, especially in the field of neurodegenerative disease. Alzheimer's disease is the most common type of neurodegenerative disease that causes dementia and has become a global health problem that seriously impacts human health today. In this review, we discuss the therapeutic potential of cannabinoids for the treatment of Alzheimer's disease. How cannabinoids act on different endocannabinoid receptor subtypes to regulate Alzheimer's disease and the roles of the endocannabinoid system in Alzheimer's disease are outlined, and the underlying mechanisms are discussed. Finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to Alzheimer's disease and discuss the potential usefulness of cannabinoids in the clinical treatment of Alzheimer's disease.
大麻素是从大麻中分离出来的化合物，也广泛存在于动物的神经系统和免疫系统中。近年来，随着对大麻素的深入研究，其临床药用价值得到了评估，许多令人兴奋的成果不断积累，特别是在神经退行性疾病领域。阿尔茨海默病是最常见的神经退行性疾病，导致痴呆，已成为当今全球严重影响人类健康的一个健康问题。在这篇综述中，我们讨论了大麻素治疗阿尔茨海默病的治疗潜力。大麻素如何作用于不同的内源性大麻素受体亚型来调节阿尔茨海默病，以及内源性大麻素系统在阿尔茨海默病中的作用，并讨论了其潜在的机制。最后，我们总结了与阿尔茨海默病相关的大麻素药理学的最相关机会，并讨论了大麻素在阿尔茨海默病临床治疗中的潜在用途。
